描述：Genemed是以技術(shù)服務(wù)為基礎(chǔ)的公司，主要提供IHC和ISH的服務(wù)，同時(shí)也提供IHC相關(guān)的全面的試劑，Genemed的生產(chǎn)符合cGMP標(biāo)準(zhǔn)，其優(yōu)勢在于提供高質(zhì)量水平的技術(shù)服務(wù)和產(chǎn)品，他們的目標(biāo)是為體外診斷試劑的研究者（不論是研究型還是商業(yè)化的）提供*的產(chǎn)品和技術(shù)服務(wù)。
www.genemed.com
Genemed是以技術(shù)服務(wù)為基礎(chǔ)的公司，主要提供IHC和ISH的服務(wù)，同時(shí)也提供IHC相關(guān)的全面的試劑，Genemed的生產(chǎn)符合cGMP標(biāo)準(zhǔn)，其優(yōu)勢在于提供高質(zhì)量水平的技術(shù)服務(wù)和產(chǎn)品，他們的目標(biāo)是為體外診斷試劑的研究者（不論是研究型還是商業(yè)化的）提供*的產(chǎn)品和技術(shù)服務(wù)。 uality is in our Genes™ At Genemed Biotechnologies, Inc., we incorporate quality from the inside out, from our dedicated employees and efficient operations to our finished products. We are cGMP-compliant and ISO-13485:2003 certified. Every part of our facility, systems, and processes are continuously monitored to ensure that we meet the highest standards of quality and customer satisfaction. We have been successfully conducting business for over 20 years in A History of Delivering Genemed Biotechnologies, Inc. was founded in 1987 and is located in the center of the South San Francisco Biotechnology community. For over 15 years, Genemed has been providing outstanding contract development and manufacturing services for well-established pharmaceutical and diagnostic companies. In 2009, to continue with our tradition of delivering excellent service, we launched our very own product lines to better serve the needs of the Biotechnology community. Advances in IHC and ISH techniques in the past decade, especially their use on formalin-fixed paraffin-embedded tissues and discovery of newer bio-molecules, result in their increasingly valuable role in surgical pathology, and increased the demands from surgical pathology services. Nowadays, in the context of a detailed morphological analysis and differential diagnosis based on the H&E staining, IHC and ISH have become major parts of the practice of diagnostic surgical pathology worldwide to help in rendering a diagnosis, classification of tumors, prediction of the likely origin of a carcinoma, demonstration of micro metastases, provision of prognostic information, justification of expensive targeted therapy （companion diagnosis）, and demonstration of microorganisms. Today, we are in an era of translational crossroads for biomarkers and personalized medicine, and IHC and ISH will remain center stage in the demonstration of newer bio-markers and their applications. Genemed’s goal is to provide superior products and services that support both academic and commercial endeavors in the area of in-vitro diagnostics and fundamental scientific research. |
